The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2017 Apr 1

PMID 28362938

Citations 78

Authors

Pranita D Tamma

Jesus Rodriguez-Bano

Affiliations

Soon will be listed here.

Abstract

The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae. The use of non-carbapenem β-lactams for the treatment of ESBL infections has yielded conflicting results. In this review, we discuss the available data for the use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infections.

Citing Articles

The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024.

Shime N, Nakada T, Yatabe T, Yamakawa K, Aoki Y, Inoue S Acute Med Surg. 2025; 12(1):e70037.

PMID: 39996161 PMC: 11848044. DOI: 10.1002/ams2.70037.

A systematic review of efficacy and safety of newer drugs approved from 2016 to 2023 for the treatment of complicated urinary tract infections.

Sivanandy P, Manirajan P, Wen Qi O, Teng Khai O, Chun Wei O, Wei Ying N Ann Med. 2024; 56(1):2403724.

PMID: 39530664 PMC: 11559027. DOI: 10.1080/07853890.2024.2403724.

Antimicrobial Resistance of spp. from Human Specimens Submitted to Diagnostic Laboratories in South Africa, 2012-2017.

Sigudu T, Oguttu J, Qekwana D Microorganisms. 2024; 12(9).

PMID: 39338536 PMC: 11433687. DOI: 10.3390/microorganisms12091862.

Effect of incremental tazobactam concentrations on the bactericidal activity of piperacillin against ESBL-producing enterobacterales clinical isolates causing bacteraemia.

Palombo M, Gatti M, Secci B, Cojutti P, Pea F, Gibellini D Eur J Clin Microbiol Infect Dis. 2024; 43(9):1861-1864.

PMID: 39017998 DOI: 10.1007/s10096-024-04879-8.

Photodynamic inactivation of antibiotic-resistant bacteria in whole blood using riboflavin photodynamic method.

Zhu L, Li C, Wang D Front Microbiol. 2024; 15:1404468.

PMID: 39015739 PMC: 11250595. DOI: 10.3389/fmicb.2024.1404468.

References

Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D . Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother. 2003; 47(11):3442-7. PMC: 253800. DOI: 10.1128/AAC.47.11.3442-3447.2003. View

Paterson D, Ko W, von Gottberg A, Mohapatra S, Casellas J, Goossens H . Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004; 39(1):31-7. DOI: 10.1086/420816. View

Craig W . Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995; 22(1-2):89-96. DOI: 10.1016/0732-8893(95)00053-d. View

Maglio D, Ong C, Banevicius M, Geng Q, Nightingale C, Nicolau D . Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother. 2004; 48(6):1941-7. PMC: 415572. DOI: 10.1128/AAC.48.6.1941-1947.2004. View

Jett B, Ritchie D, Reichley R, Bailey T, Sahm D . In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins. Antimicrob Agents Chemother. 1995; 39(5):1187-90. PMC: 162708. DOI: 10.1128/AAC.39.5.1187. View

Rice L, Yao J, Klimm K, Eliopoulos G, Moellering Jr R . Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother. 1991; 35(6):1243-4. PMC: 284322. DOI: 10.1128/AAC.35.6.1243. View

Lopez-Cerero L, Picon E, Morillo C, Hernandez J, Docobo F, Pachon J . Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli.... Clin Microbiol Infect. 2009; 16(2):132-6. DOI: 10.1111/j.1469-0691.2009.02893.x. View

Sader H, Farrell D, Flamm R, Jones R . Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect. 2014; 69(3):266-77. DOI: 10.1016/j.jinf.2014.04.004. View

Lee N, Lee C, Huang W, Tsui K, Hsueh P, Ko W . Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis. 2012; 56(4):488-95. DOI: 10.1093/cid/cis916. View

10.

Zimhony O, Chmelnitsky I, Bardenstein R, Goland S, Hammer Muntz O, Venezia S . Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother. 2006; 50(9):3179-82. PMC: 1563546. DOI: 10.1128/AAC.00218-06. View

11.

Pangon B, Bizet C, Bure A, Pichon F, Philippon A, Regnier B . In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J Infect Dis. 1989; 159(5):1005-6. DOI: 10.1093/infdis/159.5.1005. View

12.

Jean S, Coombs G, Ling T, Balaji V, Rodrigues C, Mikamo H . Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013. Int J Antimicrob Agents. 2016; 47(4):328-34. DOI: 10.1016/j.ijantimicag.2016.01.008. View

13.

Lob S, Kazmierczak K, Badal R, Hackel M, Bouchillon S, Biedenbach D . Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013. Antimicrob Agents Chemother. 2015; 59(6):3606-10. PMC: 4432174. DOI: 10.1128/AAC.05186-14. View

14.

Tripodi M, Moellering Jr R, Eliopoulos G . Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1997; 41(5):1053-7. PMC: 163849. DOI: 10.1128/AAC.41.5.1053. View

15.

Kohner P, Robberts F, Cockerill 3rd F, Patel R . Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species. J Clin Microbiol. 2009; 47(8):2419-25. PMC: 2725637. DOI: 10.1128/JCM.00508-09. View

16.

Matsumura Y, Yamamoto M, Nagao M, Tanaka M, Takakura S, Ichiyama S . In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2016; 84(4):322-7. DOI: 10.1016/j.diagmicrobio.2015.12.001. View

17.

Bush K . Proliferation and significance of clinically relevant β-lactamases. Ann N Y Acad Sci. 2013; 1277:84-90. DOI: 10.1111/nyas.12023. View

18.

Wagenlehner F, Sobel J, Newell P, Armstrong J, Huang X, Stone G . Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016; 63(6):754-762. PMC: 4996135. DOI: 10.1093/cid/ciw378. View

19.

Bradford P, Urban C, Mariano N, Projan S, Rahal J, Bush K . Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother. 1997; 41(3):563-9. PMC: 163751. DOI: 10.1128/AAC.41.3.563. View

20.

Yang C, Li S, Chuang F, Chen C, Lee C, Chen J . Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis. BMC Infect Dis. 2012; 12:206. PMC: 3507710. DOI: 10.1186/1471-2334-12-206. View